Compounded semaglutide: separating fact from telehealth marketing

What did @henry_meds actually say?

The video makes three headline claims: compounded semaglutide shares "the same active ingredients" as Ozempic or Wegovy, it suppresses appetite and lowers cravings, and it can save patients "up to 80%" compared to brand-name options. The pitch lands at $297 per month, which includes provider access, no hidden fees, and no insurance requirement. A 30-day refund policy for new customers rounds out the offer.

To be fair, this is a promotional video, not a clinical explainer. But the claims it makes touch on areas where the regulatory and scientific details actually matter, especially the ingredient equivalency framing, which is doing a lot of heavy lifting here.

Does the science back this up?

Partly. The appetite suppression claim is the most solid of the three. GLP-1 receptor agonists work by slowing gastric emptying and acting on hypothalamic satiety pathways. Wilding et al. (2021, NEJM) showed semaglutide at 2.4mg weekly produced mean weight loss of 14.9% over 68 weeks in adults with obesity, driven largely by reduced caloric intake. That mechanism is real and well-documented.

The cost savings claim is harder to verify as stated. Brand-name Wegovy lists at roughly $1,350 per month without insurance. At $297, the math for "up to 80% savings" is plausible on paper, but compounded semaglutide pricing varies significantly by pharmacy and formulation, and the "up to" framing is doing a lot of work. The FDA also issued warnings in 2023 and 2024 about compounded semaglutide products with inconsistent potency and sterility concerns, which adds context the video omits entirely.

What did they get wrong (or right)?

The ingredient equivalency claim is where the video steps into genuinely problematic territory. Saying compounded semaglutide has "the same active ingredients" as Ozempic or Wegovy is not the same as saying it is equivalent to those drugs. The FDA has been explicit about this distinction. Compounded drugs are not FDA-approved, they are not required to demonstrate bioequivalence, and their manufacturing is not held to the same standards as brand-name products.

The FDA placed semaglutide on its shortage list, which temporarily permitted compounding under specific conditions, but that status has shifted. In early 2025, the FDA declared the shortage resolved for certain semaglutide products, which affects the legal basis for compounding at scale. The video makes none of this clear.

On the appetite suppression claim, credit where it is due. That part is accurate and consistent with the published pharmacology.

What should you actually know?

If you are considering compounded semaglutide, the ingredient claim is not the right question to anchor your decision on. The right questions are: Is the compounding pharmacy 503A or 503B accredited? Has the product been independently tested for potency and sterility? What is the provider's clinical protocol for dose titration and monitoring?

A 30-day refund policy is a nice consumer protection, but it does not substitute for clinical oversight. GLP-1 medications require ongoing monitoring for side effects including nausea, pancreatitis risk, and, in patients with a history of medullary thyroid carcinoma, contraindicated use entirely. Davies et al. (2021, Lancet) documented meaningful adverse event rates even in well-controlled trial settings.

The cost access argument is real and worth taking seriously. Brand-name GLP-1 drugs are priced out of reach for most uninsured Americans. Compounded options have filled a genuine gap. But that does not make all compounded products equivalent or equally safe, and a video that leads with "shock you" framing while skipping the regulatory caveats is not giving you the full picture.